Historical Perspective of the Renin-angiotensin System

Overview

Journal Mol Biotechnol

Publisher Springer

Specialties Biotechnology
Molecular Biology

Date 2003 May 2

PMID 12721494

Citations 32

Authors

John E Hall

Affiliations

Soon will be listed here.

Abstract

Researchers continue to be fascinated with the renin-angiotensin system (RAS) more than 100 yr after its discovery because of its powerful role in controlling sodium balance, body fluid volumes, and arterial pressure. Development of drugs that block different components of this system has led to powerful treatments for hypertension, heart failure, diabetes, and other diseases. Molecular approaches to studying this system offer new possibilities for better understanding the physiology and pathophysiology of the RAS, and for developing new therapeutic paradigms. Our challenge in the future will be to effectively utilize the technological advances that are taking place in virtually all areas of science, including the RAS, and to translate them into a better understanding of the pathophysiology and treatment of human diseases.

Citing Articles

Targeting the Renin-angiotensin-aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review.

Pawlonka J, Buchalska B, Buczma K, Borzuta H, Kaminska K, Cudnoch-Jedrzejewska A Curr Treat Options Oncol. 2024; 25(11):1406-1427.

PMID: 39422794 PMC: 11541340. DOI: 10.1007/s11864-024-01270-9.

Spontaneous and evoked angiotensin II sniffer cell activity in the lamina terminalis in vitro.

Farmer G, Cunningham J Am J Physiol Regul Integr Comp Physiol. 2024; 327(5):R486-R496.

PMID: 39133776 PMC: 11563642. DOI: 10.1152/ajpregu.00227.2023.

Radiation Induced Skin Fibrosis (RISF): Opportunity for Angiotensin II-Dependent Intervention.

Boothe P, Kumar V, Kong Y, Wang K, Levinson H, Mu D Int J Mol Sci. 2024; 25(15).

PMID: 39125831 PMC: 11312688. DOI: 10.3390/ijms25158261.

AT2R Activation Improves Wound Healing in a Preclinical Mouse Model.

Harrison J, Leong E, Osborne N, Marshall J, Bezuhly M Biomedicines. 2024; 12(6).

PMID: 38927444 PMC: 11200587. DOI: 10.3390/biomedicines12061238.

The effect of tannic acid on renal renin-angiotensin signaling pathway in a model of unilateral ureteral obstruction in male Wistar rats.

Kianfar T, Kadkhodaee M, Seifi B, Abdi A, Adelipour M, Pishkenari B Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(12):3569-3579.

PMID: 37249615 DOI: 10.1007/s00210-023-02548-9.

References

Brunner H, Gavras H, LARAGH J . Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet. 1973; 2(7837):1045-8. DOI: 10.1016/s0140-6736(73)92657-3. View

Haber E, Koerner T, PAGE L, KLIMAN B, Purnode A . Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969; 29(10):1349-55. DOI: 10.1210/jcem-29-10-1349. View

ONDETTI M, Williams N, SABO E, Pluscec J, Weaver E, Kocy O . Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry. 1971; 10(22):4033-9. DOI: 10.1021/bi00798a004. View

Boyd G, FITZ A, Adamson A, Peart W . Radioimmunoassay determination of plasma-renin activity. Lancet. 1969; 1(7588):213-8. DOI: 10.1016/s0140-6736(69)91237-9. View

Schuster V, Kokko J, Jacobson H . Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules. J Clin Invest. 1984; 73(2):507-15. PMC: 425042. DOI: 10.1172/JCI111237. View

LARAGH J, ANGERS M, KELLY W, Lieberman S . Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man. JAMA. 1960; 174:234-40. DOI: 10.1001/jama.1960.03030030014003. View

Bakhle Y . Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature. 1968; 220(5170):919-21. DOI: 10.1038/220919a0. View

Gavras H, Brunner H, Vaughan E, LARAGH J . Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science. 1973; 180(4093):1369-71. DOI: 10.1126/science.180.4093.1369. View

Ames R, BORKOWSKI A, Sicinski A, LARAGH J . PROLONGED INFUSIONS OF ANGIOTENSIN II AND NOREPINEPHRINE AND BLOOD PRESSURE, ELECTROLYTE BALANCE, AND ALDOSTERONE AND CORTISOL SECRETION IN NORMAL MAN AND IN CIRRHOSIS WITH ASCITES. J Clin Invest. 1965; 44:1171-86. PMC: 292592. DOI: 10.1172/JCI105224. View

10.

GUYTON A, Coleman T . Quantitative analysis of the pathophysiology of hypertension. Circ Res. 1969; 24(5 Suppl):1-19. View

11.

FASCIOLO J, HOUSSAY B, Taquini A . The blood-pressure raising secretion of the ischaemic kidney. J Physiol. 1938; 94(3):281-93. PMC: 1393762. DOI: 10.1113/jphysiol.1938.sp003680. View

12.

Kimbrough Jr H, Vaughan Jr E, Carey R, Ayers C . Effect of intrarenal angiotensin II blockade on renal function in conscious dogs. Circ Res. 1977; 40(2):174-8. DOI: 10.1161/01.res.40.2.174. View

13.

ONDETTI M, Rubin B, Cushman D . Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science. 1977; 196(4288):441-4. DOI: 10.1126/science.191908. View

14.

Gross F . [Renin and hypertension, physiological or pathological agents?]. Klin Wochenschr. 1958; 36(15):693-706. DOI: 10.1007/BF01493136. View

15.

SELKURT E, HALL P, Spencer M . Influence of graded arterial pressure decrement on renal clearance of creatinine, p-aminohippurate and sodium. Am J Physiol. 1949; 159(2):369-78. DOI: 10.1152/ajplegacy.1949.159.2.369. View

16.

Mulrow P, Ganong W . Stimulation of aldosterone secretion by angiotensisn. II. A preliminary report. Yale J Biol Med. 1961; 33:386-95. PMC: 2604161. View

17.

Harris P, Young J . Dose-dependent stimulation and inhibition of proximal tubular sodium reabsorption by angiotensin II in the rat kidney. Pflugers Arch. 1977; 367(3):295-7. DOI: 10.1007/BF00581370. View

18.

BUMPUS F, Schwarz H, PAGE I . Synthesis and pharmacology of the octapeptide angiotonin. Science. 1957; 125(3253):886-7. DOI: 10.1126/science.125.3253.886. View

19.

SKEGGS Jr L, MARSH W, Kahn J, Shumway N . The purification of hypertensin I. J Exp Med. 1954; 100(4):363-70. PMC: 2136385. DOI: 10.1084/jem.100.4.363. View

20.

Anderson S, Rennke H, Brenner B . Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986; 77(6):1993-2000. PMC: 370560. DOI: 10.1172/JCI112528. View